These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22524576)

  • 21. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
    Guo Y; Xiong BH; Zhang T; Cheng Y; Ma L
    Cancer Invest; 2016; 34(2):94-104. PubMed ID: 26864862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
    Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
    Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.
    Inanc M; Er O; Karaca H; Berk V; Ozkan M; Dikilitas M; Elmali F
    J BUON; 2013; 18(2):391-7. PubMed ID: 23818351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
    Narita Y; Taniguchi H; Komori A; Nitta S; Yamaguchi K; Kondo C; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):409-16. PubMed ID: 24322376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer.
    Reynolds J; Chamberland-Tremblay A; Herrington JD; Munoz Maldonado Y; Wong L
    J Oncol Pharm Pract; 2017 Apr; 23(3):173-178. PubMed ID: 26786027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer.
    Tsai HL; Chang YT; Chu KS; Chen CF; Yeh YS; Ma CJ; Wu DC; Kuo CH; Chan HM; Sheen MC; Wang JY
    Int J Biol Markers; 2008; 23(4):244-8. PubMed ID: 19199273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
    Loree JM; Mulder KE; Ghosh S; Spratlin JL
    Clin Colorectal Cancer; 2014 Sep; 13(3):172-7. PubMed ID: 24630275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
    Nagai Y; Beppu T; Sakamoto Y; Miyamoto Y; Hayashi H; Nitta H; Imai K; Masuda T; Okabe H; Hirashima K; Imamura Y; Baba Y; Chikamoto A; Baba H
    Anticancer Res; 2014 Oct; 34(10):5529-35. PubMed ID: 25275051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
    Kim JG; Chae YS; Sohn SK; Moon JH; Ryoo HM; Bae SH; Kum Y; Jeon SW; Lim KH; Kang BM; Park IJ; Choi GS; Jun SH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):953-60. PubMed ID: 19219602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
    Chay WY; Tan SH; Lo YL; Ong SY; Ng HC; Gao F; Koo WH; Choo SP
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):270-7. PubMed ID: 21114776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Capecitabine-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer.
    Cokmert S; Demir L; Can A; Akyol M; Vedat Bayoglu I; Dirican A; Kucukzeybek Y; Erten C; Oktay Tarhan M
    J BUON; 2014; 19(1):75-82. PubMed ID: 24659646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy.
    Lin GN; Liu PP; Liu DY; Peng JW; Xiao JJ; Xia ZJ
    Chin J Cancer; 2016 Jan; 35():5. PubMed ID: 26740116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
    Lucchetta M; Lonardi S; Bergamo F; Alberti P; Velasco R; Argyriou AA; Briani C; Bruna J; Cazzaniga M; Cortinovis D; Cavaletti G; Kalofonos HP
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):899-902. PubMed ID: 23108696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
    Dirican A; Kucukzeybek Y; Alacacioglu A; Varol U; Aksun S; Bayoglu IV; Demir L; Coban E; Sutcu R; Tarhan MO
    Med Oncol; 2014 Apr; 31(4):905. PubMed ID: 24596030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adjuvant chemotherapy comprising modified FOLFOX6 after curative resection of synchronous or metachronous metastasis from colorectal cancer].
    Hatano S; Ishibashi K; Amano K; Ishiguro T; Kuwabara K; Sobajima J; Ohsawa T; Okada N; Kumagai Y; Kumamoto K; Baba H; Tsuji Y; Haga N; Ishida H
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2192-4. PubMed ID: 23268020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer.
    Hansen TF; Garm Spindler KL; Andersen RF; Lindebjerg J; Brandslund I; Jakobsen A
    Pharmacogenomics J; 2011 Feb; 11(1):53-60. PubMed ID: 20125120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.
    Teitelbaum UR; Haller DG
    Nat Rev Clin Oncol; 2009 May; 6(5):250-1. PubMed ID: 19390547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.